2Eknoyan G, Beck G J, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis [ J ]. N Engl J Med, 2002, 347 (25) : 2010-2019.
3Malyszko JS, Malyszko J, Hryszko T, et al. Markers of endothelial damage in patients on hemodialysis and hemodiafiltration [ J ]. J Nephrol, 2006, 19(2): 150-154.
4Raggi P, Vukicevic S, Moyses RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders [ J ]. Clin J Am Soc Nephrol, 2010, 5 (Suppl 1 ) : $31-$40.
5Penne EL, van der Weerd NC, Grooteman MP, et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients [ J ]. Clin J Am Soe Nephrol, 2011, 6(2) : 281-289.
6Kong X, Zhang L, Zhang L, et al. Mineral and bone disorder in Chinese dialysis patients: a muhicenter study [ J ]. BMC Nephrology, 2012, 13 : 116.
7Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population [ J ]. Nephrol Dial Transplant, 2011, 26 ( 6 ) : 1948- 1955.
8Shidara K, Inaba M, Okuno S, et al. Influence of nutritional status on serum large N-truncated PTH, but not PTH (1-84) in hemodialysis patients [ ]]. Biomed Pharmacother, 2007,61 (2/3) : 142-147.
9Lugon JR, Andre ME, Duarte ME, et al. Effects of incenter daily hemodialysis upon mineral metabolism and bone disease in end-stage renal disease patients [J]. Sao Paulo Med J, 2001, 119(3) : 105- 109.
10Jordi B, Llach F. Renal osteodystrophies [ M ]//Brenner and Rector. The Kidney. Sixth edition. Singapore: Harcourt Asia WBSaunde~, 2001: 2013-2186.
